Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Freedom to Heal Act creates a new registration process that allows physicians to administer experimental Schedule I drugs (the most heavily controlled drug category) to terminally ill patients under the existing federal Right to Try law. Introduced in December 2025 with bipartisan support, the bill requires doctors to apply to the Attorney General with proof they can legally prescribe controlled substances, documentation from the drug manufacturer, and evidence of relevant medical training. The Attorney General must approve or reject applications within 45 days, and physicians can request additional drug quantities with a 30-day approval process. The bill requires the Attorney General to issue detailed regulations within 240 days of enactment to establish safeguards against drug diversion, with final rules due within two years. This legislation essentially removes the current barrier preventing Schedule I drugs from being used in Right to Try cases, which already exists as law but has been limited to less-controlled drug categories.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.